Andrew Messick is an experienced finance professional currently serving as Chief Financial Officer at Kymanox since April 2025. Previously, Andrew held the position of Chief Financial Officer at Sabai Global from September 2020 to April 2025, overseeing financial operations for various subsidiaries in the clinical research and biosafety sectors. Andrew has also contributed as Chief Financial Officer at PeriGen, where responsibilities included financial strategy and transition management during the company’s relocation, and served in key financial roles at WCG and Copernicus Group IRB. Additional experience encompasses positions at Wachovia, Durking Group LLC, and Ernst & Young. Andrew holds a Master’s degree in Accountancy and a Bachelor of Science in Business Administration from UNC Kenan-Flagler Business School.
This person is not in any teams
This person is not in any offices